Cambrex
CBM | US
Overview
Corporate Details
- ISIN(s):
- US1320111073
- LEI:
- 4Q9DLX2VIFGJMOYJ4Y35
- Country:
- United States of America
- Address:
- N/A
- Website:
- https://www.cambrex.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Cambrex filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cambrex
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cambrex via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
France
ALDVI
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Sweden
AEGIR
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
France
AELIS
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
United States of America
AEON
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
Japan
2927
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
United States of America
AGEN
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO
United States of America
AGIO
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
United States of America
AKTX
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
United States of America
AKBA